Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Malignant solid tumor or lymphoma refractory to standard therapy or for which no therapy of proven benefit exists
• •No leukemia
• •Measurable or evaluable disease
• •PATIENT CHARACTERISTICS:
• •Age: 18 and over
• •Performance status: Karnofsky 70-100%
• •Life expectancy: At least 3 months
• •WBC at least 3,500/mm3
• •Absolute neutrophil count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •Hemoglobin at least 9 g/dL
• •Bilirubin no greater than 1.5 mg/dL
• •AST/ALT less than twice normal (unless due to disease)
• •PT and PTT normal
• •Creatinine no greater than 1.5 mg/dL
• •Creatinine clearance at least 60 mL/min
• •No history of congestive heart failure requiring medical therapy
• •No clinically significant or life threatening cardiac arrhythmia
• •No history of significant pulmonary disease or lymphangitic lung disease
• •No hypersensitivity to cyclosporine or cremophore
• •No history of manifest or latent porphyria or hypersensitivity to barbiturates (for parts of study using phenobarbital)
• •No history of inflammatory bowel disease requiring therapy
• •No chronic diarrhea syndrome or paralytic ileus
• •No medical or psychiatric condition that precludes informed consent
• •Not pregnant
• •Effective contraception required of fertile women
• •PRIOR CONCURRENT THERAPY:
• •At least 4 weeks since prior biologic therapy
• •At least 2 weeks since prior colony stimulating factors
• •At least 4 weeks since prior chemotherapy (at least 6 weeks since nitrosoureas or mitomycin)
• •No prior bleomycin or irinotecan
• •At least 4 weeks since prior radiotherapy to greater than 25% of bone marrow
• •Minimum time interval between prior therapy and eligibility shortened by 2 weeks when phenobarbital is administered
• •Concurrent use of medications that affect the central nervous or cardiovascular systems (e.g., anticonvulsants, calcium channel blockers, oral contraceptives) must be approved by the Principal Investigator